IBS

FDA Issues Warning for EluxadolineAnti-IBS drug Viberzi (eluxadoline) increases risk of severe pancreatitis.
FDA drug approvals-May 2015FDA actions in brief, complete response, breakthrough therapy designation, fast-track designations, orphan drug designations
New peppermint oil formulation helps quiet IBS symptomsA new formulation of peppermint oil has been shown to relieve severe IBS symptoms in adults.
Irritable bowel syndrome therapeutics market dynamics
Irritable bowel syndrome therapeutics market dynamicsCurrently, the IBS treatment market is naïve and underpenetrated, with only 4 products indicated for IBS in the 7MM.
Linzess (Linaclotide)New molecular entity: FDA approved linaclotide (Linzess, Ironwood Pharmaceuticals and Forest Pharmaceuticals) for the treatment of chronic idiopathic constipation and irritable bowel syndrome (IBS) with constipation in adults.